Financings

• Columbia Laboratories Inc. raised about $11.77 million in a registered direct sale of stock and warrants.

• Inhibitex Inc. completed its previously announced $23 million private placement of stock and warrants.

• Probiodrug AG raised $53.4 million in a Series B round for Alzheimer's disease drugs.

• Pulmatrix Inc. got $30 million in a Series B round for influenza and respiratory disease drugs.

• StemCells Inc. closed its previously announced $12.5 million registered direct offering of stock and warrants.

• Zyngenia Inc. raised $10 million in Series A funding for multi-targeted antibody-like molecules.

Deals

• Amylin Pharmaceuticals Inc. signed a $1 billion-plus deal to co-develop obesity drugs with Takeda Pharmaceutical Co. Ltd.

• Micromet Inc. bought back MedImmune's rights to BiTE antibody blinatumomab (no terms).

. . . And More

• Refer back to BioWorld Today for all the news from annual meeting of the American Association Study of Liver Diseases (AASLD), the American Society of Nephrology (ASN) meeting, the annual meeting of the Infectious Diseases Society of America (IDSA), and more.

• Amylin Pharmaceuticals Inc. expanded its FDA approval of diabetes drug Byetta (exenatide) to cover first-line monotherapy use.

• Chelsea Therapeutics International Ltd. is trying to change the primary endpoint in its second pivotal trial of droxidopa in neurogenic orthostatic hypotension.

• Dendreon Corp. submitted its biologics license application for prostate cancer vaccine Provenge (sipuleucel-T).

• GTx Inc. got a complete response letter from the FDA asking for new trials of toremifene for reducing bone fractures in prostate cancer.

• Human Genome Sciences Inc.'s Benlysta (belimumab) met its endpoints at the higher dose in its second Phase III lupus trial.

• Idenix Pharmaceuticals Inc.'s Phase I HCV drug IDX-184 was passed over by option-holder Novartis AG.

• InterMune Inc. filed for FDA approval of pirfenidone in idiopathic pulmonary fibrosis.

• Ironwood Pharmaceuticals Inc. and partner Forest Laboratories Inc. said two pivotal Phase III trials of chronic constipation drug linaclotide met their endpoints.

• SkyePharma plc and Mundipharma International Corp. Ltd. reported that the final Phase III trial of Flutiform (fluticasone 500 mcg/formoterol 20 mcg) met its endpoints at the high dose.